Volume 9 Supplement 2

Parasite to Prevention: Advances in the understanding of malaria

Open Access

Viral vectored transmission blocking vaccines against Plasmodium falciparum

  • Melissa C Kapulu1,
  • Sumi Biswas1,
  • Andrew Blagborough2,
  • Sarah C Gilbert1,
  • Robert E Sinden2 and
  • Adrian VS Hill1
Malaria Journal20109(Suppl 2):O22

https://doi.org/10.1186/1475-2875-9-S2-O22

Published: 20 October 2010

Background

Transmission blocking vaccines (TBVs) target sexual develop¬ment of the parasite within the mosquito and aim to prevent transmission of malaria from one individual to another. Antibodies raised against Pfs48/45, Pfs230 Region C, PfHAP2, and Anopheles gambiae Alanyl Aminopeptidase N1 (AgAPN1) proteins reduce transmission i.e. have transmission blocking activity [15]. Recombinant simian Adenovirus (AdC63 serotype) and Modified Vaccinia Ankara (MVA) viral vectors have been shown to induce high antibody titres to asexual parasite antigens in animal studies [6].

Materials and methods

Protein sequences for each of the antigens were codon optimised for expression in humans and cloned into shuttle vectors, which were then recombined with the parental virus and purified to obtain virus expressing the antigen of interest. Mice were vaccinated with AdC63 (i.m.), sera was taken after 2 weeks, and will be followed by an MVA boost (i.d.) eight weeks after the prime. Antibodies were assayed by a standardised ELISA, and transmission blocking activity assessed using a standardised membrane feeding assay (SMFA).

Conclusion

Induction of high antibody tires using this vaccine platform could be used together with other control measures to achieve elimination and/or eradication of the disease at a local or national level.

Authors’ Affiliations

(1)
Jenner Institute, University of Oxford
(2)
Division of Cell and Molecular Biology, Sir Alexander Fleming Building, Imperia College London

References

  1. Dinglasan RR, Kalume DE, Kanzok SM, Ghosh AK, Muratova O, Pandey A, Jacobs-Lorena M: Disruption of Plasmodium falciparum development by antibodies against a conserved mosquito midgut antigen. Proc Natl Acad Sci USA. 2007, 104: 13461-6. 10.1073/pnas.0702239104.PubMed CentralView ArticlePubMedGoogle Scholar
  2. Chowdhury DR, Angov E, Kariuki T, Kumar N: A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli. PLoS One. 2009, 4: e6352-10.1371/journal.pone.0006352.PubMed CentralView ArticlePubMedGoogle Scholar
  3. Bustamante PJ, Woodruff DC, Oh J, Keister DB, Muratova O, Williamson KC: Differential ability of specific regions of Plasmodium falciparum sexual-stage antigen, Pfs230, to induce malaria transmission-blocking immunity. Parasite Immunol. 2000, 22: 373-80. 10.1046/j.1365-3024.2000.00315.x.View ArticlePubMedGoogle Scholar
  4. Blagborough AM, Sinden RE: Plasmodium berghei HAP2 induces strong malaria transmission-blocking immunity in vivo and in vitro. Vaccine. 2009, 27: 5187-94. 10.1016/j.vaccine.2009.06.069.View ArticlePubMedGoogle Scholar
  5. Vermeulen AN, Ponnudurai T, Beckers PJ, Verhave JP, Smits MA, Meuwissen JH: Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito. J Exp Med. 1985, 162: 1460-76. 10.1084/jem.162.5.1460.View ArticlePubMedGoogle Scholar
  6. Draper SJ, Moore AC, Goodman AL, Long CA, Holder AA, Gilbert SC, Hill F, Hill AV: Effective induction of high-titer antibodies by viral vector vaccines. Nat Med. 2008, 14: 819-821. 10.1038/nm.1850.View ArticlePubMedGoogle Scholar

Copyright

© Kapulu et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Advertisement